(BMEZ) BlackRock Health Sciences - Ratings and Ratios
Biotech, Pharmaceuticals, Medical Devices, Healthcare Services
BMEZ EPS (Earnings per Share)
BMEZ Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 14.3% |
| Value at Risk 5%th | 23.2% |
| Reward | |
|---|---|
| Sharpe Ratio | 0.18 |
| Alpha | -5.32 |
| Character | |
|---|---|
| Hurst Exponent | 0.414 |
| Beta | 0.585 |
| Drawdowns 3y | |
|---|---|
| Max DD | 18.41% |
| Mean DD | 4.90% |
Description: BMEZ BlackRock Health Sciences August 14, 2025
BlackRock Health Sciences Trust II (BMEZ) is a closed-end investment fund that focuses on the healthcare sector, specifically on healthcare services. As a common stock listed on the NYSE, its performance is influenced by the overall healthcare industry trends and economic conditions.
The funds investment strategy is centered around the healthcare services sub-industry, which includes companies providing healthcare services, such as hospitals, healthcare facilities, and medical services providers. The demand for healthcare services is driven by demographic factors, such as an aging population, and economic factors, such as GDP growth and government healthcare spending.
Key performance indicators (KPIs) to monitor for BMEZ include its net asset value (NAV) growth, dividend yield, and the overall performance of its underlying portfolio. The funds NAV is influenced by the market value of its holdings, which are primarily composed of healthcare services companies. A rising NAV indicates a positive performance of the funds investments.
Economic drivers that impact BMEZs performance include government policies and regulations affecting the healthcare industry, technological advancements in healthcare, and demographic changes. For instance, an increase in government spending on healthcare programs or a rise in the prevalence of chronic diseases can positively impact the demand for healthcare services, thereby benefiting the fund.
To evaluate BMEZs investment potential, one should examine its market capitalization, price-to-earnings (P/E) ratio, and dividend yield in comparison to its peers and the broader healthcare sector. A high P/E ratio, such as 67.43, may indicate that the fund is trading at a premium to its earnings, potentially making it less attractive to income-focused investors.
From a trading perspective, monitoring BMEZs price movements, trading volume, and volatility can provide insights into market sentiment and potential trading opportunities. The funds average trading volume and ATR (average true range) can help investors gauge liquidity and potential price swings.
BMEZ Stock Overview
| Market Cap in USD | 918m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 2020-01-29 |
| Return 12m vs S&P 500 | -8.97% |
| Analyst Rating | - |
BMEZ Dividends
| Dividend Yield | 13.66% |
| Yield on Cost 5y | 12.75% |
| Yield CAGR 5y | 17.06% |
| Payout Consistency | 97.7% |
| Payout Ratio | 846.8% |
BMEZ Growth Ratios
| CAGR | 9.39% |
| CAGR/Max DD Calmar Ratio | 0.51 |
| CAGR/Mean DD Pain Ratio | 1.91 |
| Current Volume | 195.1k |
| Average Volume | 191k |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (43.5m TTM) > 0 and > 6% of Revenue (6% = 2.28m TTM) |
| FCFTA -0.00 (>2.0%) and ΔFCFTA -5.41pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 69.39% (prev 24.88%; Δ 44.51pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.00 (>3.0%) and CFO -970.2k <= Net Income 43.5m (YES >=105%, WARN >=100%) |
| Net Debt (-71.3k) to EBITDA (43.5m) ratio: -0.00 <= 3.0 (WARN <= 3.5) |
| Current Ratio 153.7 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (13.3m) change vs 12m ago NaN% (target <= -2.0% for YES) |
| Gross Margin 67.45% (prev 95.20%; Δ -27.75pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 5.51% (prev 1.35%; Δ 4.16pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 100.0k (EBITDA TTM 43.5m / Interest Expense TTM 78.0) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 40.95
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield -0.11% = -0.05 |
| 3. FCF Margin -2.55% = -0.96 |
| 4. Debt/Equity 0.00 = 2.50 |
| 5. Debt/Ebitda -0.00 = 2.50 |
| 6. ROIC - WACC (= -3.53)% = -4.42 |
| 7. RoE 6.77% = 0.56 |
| 8. Rev. Trend -59.66% = -4.47 |
| 9. EPS Trend -54.13% = -2.71 |
What is the price of BMEZ shares?
Over the past week, the price has changed by -1.21%, over one month by +0.06%, over three months by +9.68% and over the past year by +4.87%.
Is BlackRock Health Sciences a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BMEZ is around 15.99 USD . This means that BMEZ is currently overvalued and has a potential downside of 8.92%.
Is BMEZ a buy, sell or hold?
What are the forecasts/targets for the BMEZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 17.8 | 21.1% |
BMEZ Fundamental Data Overview November 11, 2025
P/S = 23.3725
P/B = 0.9492
Beta = None
Revenue TTM = 38.0m USD
EBIT TTM = 43.5m USD
EBITDA TTM = 43.5m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 278.1k USD (from shortTermDebt, last quarter)
Debt = 278.1k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -71.3k USD (from netDebt column, last quarter)
Enterprise Value = 891.2m USD (917.5m + Debt 278.1k - CCE 26.6m)
Interest Coverage Ratio = 558.1k (Ebit TTM 43.5m / Interest Expense TTM 78.0)
FCF Yield = -0.11% (FCF TTM -970.2k / Enterprise Value 891.2m)
FCF Margin = -2.55% (FCF TTM -970.2k / Revenue TTM 38.0m)
Net Margin = 114.3% (Net Income TTM 43.5m / Revenue TTM 38.0m)
Gross Margin = 67.45% ((Revenue TTM 38.0m - Cost of Revenue TTM 12.4m) / Revenue TTM)
Gross Margin QoQ = 6.91% (prev none%)
Tobins Q-Ratio = 1.15 (Enterprise Value 891.2m / Total Assets 774.6m)
Interest Expense / Debt = 0.03% (Interest Expense 78.0 / Debt 278.1k)
Taxrate = 21.0% (US default 21%)
NOPAT = 34.4m (EBIT 43.5m * (1 - 21.00%))
Current Ratio = 153.7 (out of range, set to none) (Total Current Assets 26.6m / Total Current Liabilities 172.8k)
Debt / Equity = 0.00 (Debt 278.1k / totalStockholderEquity, last quarter 768.6m)
Debt / EBITDA = -0.00 (Net Debt -71.3k / EBITDA 43.5m)
Debt / FCF = 0.07 (negative FCF - burning cash) (Net Debt -71.3k / FCF TTM -970.2k)
Total Stockholder Equity = 642.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.61% (Net Income 43.5m / Total Assets 774.6m)
RoE = 6.77% (Net Income TTM 43.5m / Total Stockholder Equity 642.6m)
RoCE = 6.77% (EBIT 43.5m / Capital Employed (Equity 642.6m + L.T.Debt 0.0))
RoIC = 4.63% (NOPAT 34.4m / Invested Capital 742.1m)
WACC = 8.17% (E(917.5m)/V(917.8m) * Re(8.17%) + D(278.1k)/V(917.8m) * Rd(0.03%) * (1-Tc(0.21)))
Discount Rate = 8.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -58.80%
Fair Price DCF = unknown (Cash Flow -970.2k)
EPS Correlation: -54.13 | EPS CAGR: -91.43% | SUE: 0.11 | # QB: 0
Revenue Correlation: -59.66 | Revenue CAGR: -87.40% | SUE: N/A | # QB: 0
Additional Sources for BMEZ Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle